Physician profile
Jill Willard
NPI 1316381593
$2,827.15
in general payments reported to CMS, 2019-2025
44 companies · $38.91 in 2025
The $38.91 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $715 · 2022: $1,539 · 2023: $345 · 2024: $189 · 2025: $38.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $327.30 | 2022-2024 | |
| Lilly USA, LLC | $255.58 | 2021-2024 | Retevmo, Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $196.41 | 2021-2023 | Opdivo |
| Genzyme Corporation | $186.22 | 2021-2023 | |
| Eisai INC. | $154.27 | 2021-2022 | |
| Seagen INC. | $142.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $124.34 | 2021-2023 | Enhertu |
| Daiichi Sankyo INC. | $115.81 | 2021-2022 | |
| Celgene Corporation | $111.78 | 2022-2024 | Reblozyl |
| Amgen INC. | $111.41 | 2021-2022 | |
| Gilead Sciences, INC. | $106.46 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $104.48 | 2021-2024 | Keytruda, Lynparza |
| Incyte Corporation | $100.50 | 2022 | |
| Janssen Biotech, INC. | $70.55 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $58.79 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Willard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.